

Regulus Therapeutics Inc. Investor Relations Department 10614 Science Center Dr San Diego, CA 92121 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: RGLS	
Last Trade:	1.19
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.08 👚 (+7.207%)
Day Range	1.14 - 1.28
52-Week Range	0.86 - 4.25
Volume	3,035,874

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a wellbalanced *microRNA* therapeutics pipeline complemented by a maturing *micro*Markers<sup>SM</sup> biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is developing RG-101, a GalNAc-conjugated antimiR targeting *microRNA*-122 for the tre... (more)

#### **Stock Performance**



## Press Releases [View all]

Jul 25, 2017

Regulus Announces Completion of Public
Offering of Common Stock and Exercise in
Full of Underwriters' Option to Purchase
Additional Shares

Jul 25, 2017

Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017

Jul 19, 2017

Regulus Announces Pricing of Public Offering of Common Stock

Jul 19, 2017

Regulus Announces Commencement of Public Offering of Common Stock

Jun 13, 2017

Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer

### Upcoming Events [View all]

Aug 1, 2017 5:00 PM ET
Regulus Therapeutics Inc. Second Quarter 2017
Conference Call

### Financials [View all]

First Quarter Financial Results

Mar 3. 2017

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 2, 2016

Quarterly Report (10-Q)

Aug 3, 2016

Quarterly Report (10-Q)